Advanced Search:
Equity Index

SIGHT.PA - GENSIGHT BIOLOGICS

€0.40  0.006 (1.52%)

Updated: 11:48 May 5, 2024 EST

Next Session's AI Forecast

82.01%

Avg. Accuracy (AI)

€0.33

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

€0.41

GENSIGHT BIOLOGICS's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

GENSIGHT BIOLOGICS - HISTORICAL DATA 6M

  • Last price

    €0.40

  • Daily change

    €0.006

  • Previous Close

    €0.396

  • Last Updated

    11:48 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.46 -0.03 0.11 -0.27 -0.2

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.89 1.5 2.67 2.86 3.94

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 45.71% 27.12% 12.33%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

GENSIGHT BIOLOGICS Technical Analysis News

GENSIGHT BIOLOGICS

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 16
Description

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Corporate Governance

GenSight Biologics S.A.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 4; Compensation: 10.

GENSIGHT BIOLOGICS'S HOLDERS RANK

List of holders with stock participation in GENSIGHT BIOLOGICS.

Holder Rank Holder Shares Date Reported % Out Value